At Long Last, an Antidote for a NOAC!
At Long Last, an Antidote for a NOAC!One of the biggest advances in the world of nonvalvular atrial fibrillation was the introduction of the novel oral anticoagulants (NOACs) for decreasing thromboembolic risk.
Ablation Therapy for AF Who, What is it Good For1. Which of the following is probably not a characteristic of someone who has had catheter ablation for atrial fibrillation (AF)?
Atrial Fibrillation May Increase Risk of DementiaAtrial fibrillation (AF) may increase the risk of dementia, according to a new study conducted in the Netherlands. The study looked at 20 years of follow-up data on over 6000 people, and found that younger participants with a longer duration of AF had the highest risk of dementia.
AUA updates testosterone therapy position statementThe AUA has released an updated version of its position statement on testosterone therapy.
ESC '15 Real World Patients, Real World Numbers from GARFIELD-AFAtrial fibrillation (AF) has the luxury (and curse) of being one of those conditions for which large scale randomized clinical trials (such as RELY, ROCKET-AF, ARISTOTLE, ENGAGE-TIMI48) have paved the way for understanding risk and guiding disease management.
FDA approves major cholesterol drugThe FDA on August 27 approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options.
Is digoxin a last resort in Afib?Until another trial is conducted, digoxin use for patients who have other alternatives appears to be contraindicated.
Statins Do Double Duty Against StrokeA new study suggests that inpatient statin use is linked to improved outcomes after ICH, and that stopping statins during hospitalization is associated with worse outcomes.